Literature DB >> 25057958

Primary biliary cirrhosis: overlaps with other autoimmune disorders.

Annarosa Floreani1, Irene Franceschet1, Nora Cazzagon1.   

Abstract

In this article, the authors use the term "overlaps" to refer to the coexistence of primary biliary cirrhosis (PBC) with another autoimmune condition that involves the liver or extrahepatic organs. Diagnosing PBC-autoimmune hepatitis (PBC-AIH) overlap syndrome remains a challenge, especially because there is still no consensus on the most appropriate diagnostic criteria. The prevalence of this condition varies considerably among series of PBC patients, and its treatment demands a combination of ursodeoxycholic acid and immunosuppressive drugs. Overlap syndrome between PBC and primary sclerosing cholangitis is described in exceptional cases. About one in three PBC patients have a concomitant extrahepatic autoimmune disease, which may include rheumatological, endocrinological, gastrointestinal, pulmonary, or dermatological conditions. Overlaps raise several questions, about whether they share much the same genetic susceptibility, as is generally assumed. The pathogenesis of these conditions includes the production of both innate and adaptive immune responses targeting cholangiocytes as well as different extrahepatic tissues. In this sense, overlaps in PBC represent a continuous spectrum of autoimmunity involving liver and extrahepatic tissues. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25057958     DOI: 10.1055/s-0034-1383734

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  9 in total

1.  Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.

Authors:  Jennifer Y Lee; Christopher J Danford; Hirsh D Trivedi; Elliot B Tapper; Vilas R Patwardhan; Alan Bonder
Journal:  Dig Dis Sci       Date:  2019-01-10       Impact factor: 3.199

2.  Clinical significance of concomitant extrahepatic autoimmune disease in patients with autoimmune liver disease.

Authors:  Fatih Karakaya; Sura Oztekin; Yelda Ozturk; Cagdas Kalkan; Zeynep Melekoglu Ellik; Atilla Halil Elhan; Irfan Soykan; Ramazan Idilman
Journal:  Hepatol Forum       Date:  2021-01-08

3.  Natural killer cells regulate T cell immune responses in primary biliary cirrhosis.

Authors:  Shinji Shimoda; Satomi Hisamoto; Kenichi Harada; Sho Iwasaka; Yong Chong; Minoru Nakamura; Yuki Bekki; Tomoharu Yoshizumi; Ken Shirabe; Toru Ikegami; Yoshihiko Maehara; Xiao-Song He; M Eric Gershwin; Koichi Akashi
Journal:  Hepatology       Date:  2015-10-16       Impact factor: 17.425

Review 4.  Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.

Authors:  Treta Purohit; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2015-05-08

5.  The efficacy of adalimumab in psoriatic arthritis concomitant to overlapping primary biliary cholangitis and primary sclerosing cholangitis: a case report.

Authors:  Teresa Del Ross; Amelia Ruffatti; Annarosa Floreani; Ariela Hoxha; Leonardo Punzi
Journal:  BMC Musculoskelet Disord       Date:  2016-11-22       Impact factor: 2.362

6.  The extrahepatic events of Asian patients with primary biliary cholangitis: A 30-year cohort study.

Authors:  Cheng-Yu Lin; Ya-Ting Cheng; Ming-Ling Chang; Rong-Nan Chien
Journal:  Sci Rep       Date:  2019-05-20       Impact factor: 4.379

7.  Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study.

Authors:  Yuwei Liu; Kai Han; Chen Liu; Fangfang Duan; Jun Cheng; Song Yang
Journal:  Can J Gastroenterol Hepatol       Date:  2021-03-17

Review 8.  Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice.

Authors:  Federica Invernizzi; Marta Cilla; Silvia Trapani; Maria Guarino; Valentina Cossiga; Martina Gambato; Maria Cristina Morelli; Filomena Morisco; Patrizia Burra; Annarosa Floreani
Journal:  J Pers Med       Date:  2022-06-02

9.  Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up.

Authors:  Peter Deibert; Adhara Lazaro; Zoran Stankovic; Denise Schaffner; Martin Rössle; Wolfgang Kreisel
Journal:  World J Gastroenterol       Date:  2018-01-21       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.